Aromatic-Cationic Peptide Therapy for Sengers Syndrome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Sengers syndrome, a rare autosomal recessive condition caused by mutations in the mitochondrial lipid kinase acylglycerol kinase (AGK) gene, lacks effective treatments, leading to severe cardiomyopathy, skeletal myopathy, and early mortality, with current therapies only providing supportive care.
Innovation Solution
Administration of a therapeutically effective amount of the aromatic-cationic peptide D-Arg-2′6′-Dmt-Lys-Phe-NH2 or its pharmaceutically acceptable salts, such as acetate, hydrochloride, or trifluoroacetate, to increase AGK expression levels in subjects with Sengers syndrome, either through direct administration or in combination with cardiovascular agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no treatment is administered, then the disease progresses to severe cardiomyopathy and early mortality, but administering conventional supportive care only maintains current symptoms without improving AGK expression or disease outcome
Solution Approach 1:
The patent applies parameter changes by administering aromatic-cationic peptides that alter the biochemical parameters within mitochondria, specifically increasing AGK expression levels and modifying cardiolipin composition. This changes the physiological state of the mitochondria to counteract the harmful effects of AGK deficiency, thereby improving disease outcome and reducing cardiomyopathy severity.
Solution Approach 2:
The aromatic-cationic peptides act as intermediaries that deliver therapeutic effects to the mitochondria. These peptides serve as mediators between the administered treatment and the defective AGK enzyme system, facilitating increased AGK expression and improved mitochondrial function without directly replacing the defective gene.
2Object-generated harmful factors
If aromatic-cationic peptide is administered to increase AGK expression, then disease severity is reduced and cardiac function improves, but the treatment complexity and administration requirements increase
Solution Approach 1:
The aromatic-cationic peptides exhibit multi-functionality by simultaneously increasing AGK expression, improving cardiolipin composition, enhancing mitochondrial function, and reducing multiple symptoms including cardiomyopathy and skeletal myopathy. This single agent addresses multiple pathological aspects of the disease, reducing the need for multiple separate treatments.
3Duration of action of stationary object
If long-term daily peptide administration is implemented, then sustained improvement in cardiac function and AGK expression is achieved, but treatment duration and patient compliance requirements increase
Solution Approach 1:
The treatment requires continuous daily administration of the aromatic-cationic peptide to maintain sustained improvement in cardiac function and AGK expression. The continuous action of the peptide ensures ongoing mitochondrial support and prevents disease progression, necessitating long-term commitment but providing consistent therapeutic benefit.
Data Source
AI summary
The disclosure provides methods of preventing or treating Sengers syndrome in a mammalian subject, reducing risk factors associated with Sengers syndrome, and/or reducing the likelihood or severity of Sengers syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of AGK in subjects in need thereof.